Cyramza 2019 U.S. PROMOTIONAL AUDIT REPORT

Cyramza 2019 U.S. PROMOTIONAL AUDIT REPORT

  • July 2020 •
  • 26 pages •
  • Report ID: 5210266 •
  • Format: PDF
The 5 Key Questions Addressed by this Report:
• How many physicians were reached by Cyramza through reportable promotional activity in 2019 and how does this compare to its peer set in the Colorectal Cancer, Gastric Cancer, Hepatocellular Carcinoma, and Non-Small Cell Lung Cancer markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Eli Lilly’s depth of coverage vary within key specialties (e.g., Hematology/Oncology, Medical Oncology, Internal Medicine, and Radiation Oncology) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Cyramza throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Cyramza in 2019?

Data Sources and Methodology:
• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 9,100 paid interactions across 3,100 physicians made on behalf of Cyramza were carefully examined to support our analysis. In addition, interaction data from 24 peer products (e.g. Abraxane, Alecensa, Alimta, Alunbrig, Avastin, Erbitux, Gilotrif, Herceptin, Imfinzi, Kanjinti, Keytruda, Lonsurf, Lorbrena, Mvasi, Nexavar, Ogivri, Opdivo, Photofrin, Stivarga, Tagrisso, Tecentriq, Vectibix, Vizimpro, and Xalkori ) was leveraged to provide benchmarking and market insights.